Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study - PubMed (original) (raw)

Clinical Trial

. 1988 Dec;15(12):1747-54.

Affiliations

Clinical Trial

Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study

G Borg et al. J Rheumatol. 1988 Dec.

Abstract

The effect of early initiation of auranofin (AF) therapy on outcome measures was studied in a controlled 24-month double blind trial in 138 patients with early rheumatoid arthritis (RA) using an intent to treat approach. Patients were randomized to AF or placebo but in case of insufficient effect or intolerable adverse events, they switched to open disease modifying antirheumatic drug therapy. Patients who started AF fared significantly better in improved joint swelling. Stanford Health Assessment Questionnaire index, Keitel functional test, and mental depression, and furthermore, radiologic progression was significantly retarded. Our results support a disease modifying beneficial effect of AF in early active RA.se

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources